Fig. 1: VSV∆M51 elicits tumour regression in infection-resistant tumours.
a Tumour virus titers post VSV∆M51-GFP (n = 3–7 mice/group, compiled from 1 or 2 independent experiments). b Viral transgene expression in tumours post VSV∆M51-oFluc (n = 3–5 mice/group measured repeatedly over time, except non-tumour bearing (NTB), which had 2–3 mice/group, representative of 2 independent experiments). c Tumour infection 24 h post VSV∆M51-GFP, representative of n = 4 mice/group imaged over 2 independent experiments. Scale bars are 100 µm. d Overall survival of tumour-bearing mice treated with infectious or UV-irradiated VSV∆M51 ± CD8 neutralizing antibodies (αCD8, n = 4–25 mice/group, compiled from 2–3 independent experiments, log-rank Mantel–Cox test). e Infection in F7 tumours 24 h post VSV∆M51-GFP, representative of n = 6 mice imaged over 2 independent experiments. Scale bar is 300 µm. f Viral transgene expression in tumours post VSV∆M51-oFluc ± αCD8 (n = 6 mice/group (CT-26IFNmut + αCD8, F7 + αCD8), n = 7 mice/group (CT-26IFNmut), n = 10 mice/group (F7), n = 3 mice/group (NTB) measured repeatedly over time, representative of 2 independent experiments, two-way ANOVA with Dunnett’s post-test comparing F7 to CT-26IFNmut). g Overall survival of mice bearing F7 tumours post VSV∆M51 ± αCD8 (n = 13 mice/group (control), n = 17 mice/group (VSV), n = 6 mice/group (VSV + αCD8), compiled from 2 independent experiments, log-rank Mantel–Cox test of VSV∆M51 compared to control). h Overall survival of mice bearing infection-resistant M3-9-M tumours post VSV∆M51 (n = 5 mice (M3-9-MRes1 control), n = 4 mice (M3-9-MRes2 control), n = 7 mice (M3-9-MRes1 VSV, M3-9-MRes2 VSV), representative of 2 independent experiments, log-rank Mantel-Cox test). Unless otherwise indicated, VSV∆M51 was delivered i.v. at 5 × 108 PFU. Bars/points at mean ± SD. Source data are provided as a Source Data file. Occasionally n is given as a range as the number of mice in each group varies. Please see the Source Data file for the exact n in each group.
